{"preliminary_commentary":{"by_channel":{"x_thread":3,"podcast":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"BEHOLD-1","nct_id":"NCT06431594","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=behold-1-nct06431594. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with advanced solid tumors who are refractory or intolerant to established standard therapies","label":"Part 1: Dose Escalation","type":"EXPERIMENTAL"},{"description":"Participants with platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC)","label":"Part 2: Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-12-31","type":"ESTIMATED"},"conditions":["Solid Tumors","Neoplasms"],"enrollment":{"count":675,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Mocertatug rezetecan","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-25","lead_sponsor":"GlaxoSmithKline","official_title":"A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Subjects With Advanced Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-09-22","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1: Number of participants with dose limiting toxicity (DLT)","timeFrame":"Up to 21 days"},{"measure":"Part 2-Confirmed Objective Response Rate (ORR) assessed by investigator","timeFrame":"Up to approximately 28 months"}],"references":[{"citation":"Lheureux S, Provencher D, Baka S, Kowalyszyn R, Schutte T, Urun Y, Zeng X, Oaknin A, Lorusso D, Ray-Coquard I, Moreno V, Jalkanen K, Liu Burstrom L, van Dongen MGJ, Boni V, Lee JY, Bedard PL, Malinowska IA, Kaisermann M, McKean W. BEHOLD-1 and -2: phase 1/2 randomized studies evaluating the B7 homolog 4 protein-targeted antibody-drug conjugate mocertatug rezetecan in patients with solid tumors, including endometrial and ovarian cancers. Int J Gynecol Cancer. 2026 Sep 7:105607. doi: 10.1016/j.ijgc.2026.105607. Online ahead of print.","pmid":"42850140","type":"DERIVED"}],"start_date":{"date":"2024-07-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)","url":"https://clinicaltrials.gov/study/NCT06431594"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/behold-1-nct06431594"}